vTv Therapeutics (VTVT) Debt to Equity (2016 - 2023)
Historic Debt to Equity for vTv Therapeutics (VTVT) over the last 10 years, with Q1 2023 value amounting to -$0.05.
- vTv Therapeutics' Debt to Equity rose 4950.72% to -$0.05 in Q1 2023 from the same period last year, while for Mar 2023 it was -$0.05, marking a year-over-year increase of 4950.72%. This contributed to the annual value of -$0.06 for FY2022, which is 5084.68% up from last year.
- According to the latest figures from Q1 2023, vTv Therapeutics' Debt to Equity is -$0.05, which was up 4950.72% from -$0.06 recorded in Q4 2022.
- vTv Therapeutics' 5-year Debt to Equity high stood at -$0.04 for Q4 2020, and its period low was -$0.13 during Q4 2021.
- In the last 5 years, vTv Therapeutics' Debt to Equity had a median value of -$0.06 in 2022 and averaged -$0.07.
- As far as peak fluctuations go, vTv Therapeutics' Debt to Equity soared by 7965.75% in 2019, and later plummeted by 26150.19% in 2021.
- Over the past 5 years, vTv Therapeutics' Debt to Equity (Quarter) stood at -$0.05 in 2019, then surged by 32.45% to -$0.04 in 2020, then tumbled by 261.5% to -$0.13 in 2021, then surged by 50.85% to -$0.06 in 2022, then grew by 24.57% to -$0.05 in 2023.
- Its Debt to Equity stands at -$0.05 for Q1 2023, versus -$0.06 for Q4 2022 and -$0.09 for Q3 2022.